188 related articles for article (PubMed ID: 1728640)
1. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo?
Dummer R; Posseckert G; Nestle F; Witzgall R; Burger M; Becker JC; Schäfer E; Wiede J; Sebald W; Burg G
J Invest Dermatol; 1992 Jan; 98(1):50-4. PubMed ID: 1728640
[TBL] [Abstract][Full Text] [Related]
2. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.
Wasik MA; Vonderheid EC; Bigler RD; Marti R; Lessin SR; Polansky M; Kadin ME
Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482
[TBL] [Abstract][Full Text] [Related]
3. Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor alpha, beta, and gamma chains.
Dummer R; Posseckert G; Sugamura K; Grundmann H; Burg G
J Interferon Cytokine Res; 1996 Apr; 16(4):315-20. PubMed ID: 9162525
[TBL] [Abstract][Full Text] [Related]
4. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
Carson WE; Giri JG; Lindemann MJ; Linett ML; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri MA
J Exp Med; 1994 Oct; 180(4):1395-403. PubMed ID: 7523571
[TBL] [Abstract][Full Text] [Related]
5. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation.
Dummer R; Kohl O; Gillessen J; Kägi M; Burg G
Arch Dermatol; 1993 Apr; 129(4):433-6. PubMed ID: 8466213
[TBL] [Abstract][Full Text] [Related]
7. Soluble interleukin 2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells.
Zorn U; Dallmann I; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
Cytokine; 1994 Jul; 6(4):358-64. PubMed ID: 7948742
[TBL] [Abstract][Full Text] [Related]
8. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease.
Damle RN; Advani SH; Gangal SG
Int J Cancer; 1992 Jan; 50(2):192-6. PubMed ID: 1730512
[TBL] [Abstract][Full Text] [Related]
9. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
10. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
[TBL] [Abstract][Full Text] [Related]
11. Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro.
Pizzolo G; Vincenzi C; Vinante F; Rigo A; Veneri D; Chilosi M; Dusi S; Poli G; Zambello R; Semenzato G
Cell Immunol; 1992 Apr; 141(1):253-9. PubMed ID: 1555253
[TBL] [Abstract][Full Text] [Related]
12. [Soluble interleukin-2 receptor in patients with urinary bladder cancer].
Wen R; Xie S
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261
[TBL] [Abstract][Full Text] [Related]
13. The role of interleukin 2 (IL-2) and serum-soluble IL-2 receptor cells in idiopathic IgA nephropathy.
Parera M; Rivera F; Egido J; Campos A
Clin Immunol Immunopathol; 1992 May; 63(2):196-9. PubMed ID: 1351798
[TBL] [Abstract][Full Text] [Related]
14. Leukotriene B4 augments interleukin-2 receptor-beta (IL-2R beta) expression and IL-2R beta-mediated cytotoxic response in human peripheral blood lymphocytes.
Stanková J; Gagnon N; Rola-Pleszczynski M
Immunology; 1992 Jun; 76(2):258-63. PubMed ID: 1321793
[TBL] [Abstract][Full Text] [Related]
15. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
Paietta E; Nelson DL; Andersen J; Dutcher JP; Wiernik PH
Med Oncol; 1995 Jun; 12(2):121-4. PubMed ID: 8535662
[TBL] [Abstract][Full Text] [Related]
16. Release of sIL-2R alpha from and activation of native human peripheral blood mononuclear cells by recombinant IL-15.
Treiber-Held S; Stewart DM; Barraclough HA; Kurman CC; Nelson DL
Clin Immunol Immunopathol; 1996 Jul; 80(1):67-75. PubMed ID: 8674241
[TBL] [Abstract][Full Text] [Related]
17. Regulation of human large granular lymphocyte and T cell growth and function by recombinant interleukin 2: induction of interleukin 2 receptor and promotion of growth of cells with enhanced cytotoxicity.
Yamada S; Ruscetti FW; Overton WR; Herberman RB; Birchenall-Sparks MC; Ortaldo JR
J Leukoc Biol; 1987 Jun; 41(6):505-17. PubMed ID: 3110337
[TBL] [Abstract][Full Text] [Related]
18. IL-2 regulation of soluble IL-2 receptor levels following thermal injury.
Teodorczyk-Injeyan JA; Sparkes BG; Lalani S; Peters WJ; Mills GB
Clin Exp Immunol; 1992 Oct; 90(1):36-42. PubMed ID: 1382903
[TBL] [Abstract][Full Text] [Related]
19. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition.
Symons JA; Wood NC; Di Giovine FS; Duff GW
J Immunol; 1988 Oct; 141(8):2612-8. PubMed ID: 3262665
[TBL] [Abstract][Full Text] [Related]
20. Increased serum-soluble interleukin-2 receptor in burn patients: characterization and effects on the immune system.
Jobin N; Garrel D; Bernier J
Hum Immunol; 2000 Mar; 61(3):233-46. PubMed ID: 10689113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
